[Skip to Content]
[Skip to Content Landing]
November 1992

Cardiovascular Risk Factors During Estrogen-Norethindrone and Cholecalciferol Treatment

Author Affiliations

From the Department of Clinical Chemistry, Frederiksberg Hospital, Copenhagen, Denmark (Dr Myrup) and Departments of Medical Endocrinology (Dr Jensen) and Clinical Chemistry (Dr McNair), Hvidovre Hospital, University of Copenhagen.

Arch Intern Med. 1992;152(11):2265-2268. doi:10.1001/archinte.1992.00400230077013

The effect of cholecalciferol and estrogen-norethindrone treatment on total cholesterol level, high-density lipoprotein cholesterol level, blood pressure, and body mass index was investigated in 74 postmenopausal women in a doubleblind, randomized trial. Blood pressure and body mass index did not change throughout the study. We demonstrated a decrease (11%) in serum cholesterol level after 1 year of treatment with estrogen-norethindrone. When this treatment was combined with cholecalciferol, a similar decrease (13%) was observed. The hypocholesterolemic effect was correlated to body mass index in a way that indicated the most pronounced decrease in lean women. The high-density lipoprotein cholesterol/total cholesterol fraction increased by 45% after 1 year of estrogen-norethindrone treatment, while an increase of 25% after 1 year was seen when cholecalciferol was added to the treatment. The latter increase was not different from a similar increase in the placebo group. The possible dyslipidemic effect of cholecalciferol, along with the risk of hypercalcemia, emphasizes the caution necessary in cholecalciferol treatment.

(Arch Intern Med. 1992;152:2265-2268)